Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials
详细信息    查看全文
  • 作者：Yong Yu (1)
    Xun Xu (1)
    Ziyan Du (1)
    Minhua Shi (1) minhuashi11@gmail.com
  • 关键词：Carcinoma &#8211 ; Non ; small cell lung &#8211 ; Gemcitabine &#8211 ; Docetaxel &#8211 ; Platinum &#8211 ; Cisplatin &#8211 ; Carboplatin
  • 刊名：Cancer Chemotherapy and Pharmacology
  • 出版年：2012
  • 出版时间：May 2012
  • 年：2012
  • 卷：69
  • 期：5
  • 页码：1265-1275
  • 全文大小：1.0 MB
  • 参考文献：1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
    2. Novello S, Le Chevalier T (2003) Chemotherapy for non-small-cell lung cancer, Part 1: early-stage disease. Oncology (Williston Park) 17:357–364
    3. Azzoli CG, Baker SJ, Temin S et al (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251–6266
    4. NCCN Non-Small Cell Lung Cancer Panel Members (2011) Non-small cell lung cancer. NCCN clinical practice guidelines in oncology version 3, 2011. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
    5. Pujol JL, Breton JL, Gervais R et al (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602–610
    6. Georgoulias V, Ardavanis A, Tsiafaki X et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945
    7. Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478–1484
    8. Julian PT Higgins, Douglas G Altman, Jonathan AC Sterne (2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (ed) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org
    9. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834
    10. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
    11. Rubio JC, Estevez SV, Rivera FV et al (2006) Gemcitabine/Docetaxel (GD) vs Gemcitabine/Cisplatin (GC) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006 ASCO annual meeting proceedings part I, vol 24, no. 18S (June 20 Supplement): 17017
    12. Rubio JC, Estevez SV, Rivera FV et al (2006) A randomized phase IIB trial of gemcitabine and cisplatin (GC) versus gemcitabine and docetaxel (GD) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). an galician lung cancer group study. ESMO annual meeting abstract 2006. 751P
    13. Solomon B, Bunn PA Jr (2005) Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: Similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treat Rev 31:571–576
    14. Takiguchi Y, Katakami N, Yoshimori K et al (2004) Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small cell lung carcinoma (NSCLC): a randomized phase II study by the Japan lung cancer cooperative clinical study group. EMSO annual meeting abstract 2004. 635PD
    15. Georgoulias V, Ardavanis A, Tsiafaki X et al (2004) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. ESMO annual meeting abstract 2004, 637PD
    16. Binder D, Beinert T, Schweisfurth H et al (2004) Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial. ESMO Ann Meet Abstr 2004:7071
    17. Binder D, Sailer V, Schweigert M et al (2002) A randomized phase II study of gemcitabine/docetaxel vs gemcitabine/cisplatin followed by docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Society of Clinical Oncology 2002
    18. Kakolyris S, Tsiafaki X, Agelidou A et al (2002) Preliminary results of a multicentre randomised phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer [abstract]. In: Proceedings of the American Society of Clinical Oncology 2002
    19. Georgoulias V, Samonis G, Papadakis E et al (2001) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34(Suppl 4):S47–S51
    20. Georgoulias V, Papadakis E, Alexopoulos A et al (1999) Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial. ASCO annual meeting abstract 1999, Abstract No:1778
    21. Novello S, Falcone A, Crino L et al (2009) Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer 66:327–332
    22. Rubio JC, Vazquez S, Vazquez F et al (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 64:379–384
    23. Rigas JR, Carey M, Dragnev KH et al (2008) Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112. J Clin Oncol 26: May 20 suppl, abstr 8100
    24. Binder D, Schweisfurth H, Grah C et al (2007) Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Cancer Chemother Pharmacol 60:143–150
    25. Katakami N, Takiguchi Y, Yoshimori K et al (2006) Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan lung cancer cooperative clinical study group. J Thorac Oncol 1:447–453
    26. Gamaz M, Taright TMS (2006) Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2006 ASCO annual meeting proceedings part I, vol 24, no 18S (June 20 Supplement): 17116
    27. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909
    28. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2:845–853
    29. D’Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):116–119
    30. D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926–2936
    31. Chen S, Zhang J, Wang R, Luo X, Chen H (2010) The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70:63–70
  • 作者单位：1. Department of Respiratory Medicine, The Second Affiliated Hospital of Soochow University, No. 1055 SanXiang Road, Suzhou, 215004 China
  • 刊物类别：Biomedical and Life Sciences
  • 刊物主题：Biomedicine
    Cancer Research
    Pharmacology and Toxicology
    Oncology
  • 出版者：Springer Berlin / Heidelberg
  • ISSN：1432-0843
文摘
Purpose The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced non-small cell lung cancer (NSCLC).
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.